Anti-Diabetes Drugs - France | Statista Market Forecast

In France, the Anti-Diabetes Drugs market is poised to witness a significant growth in revenue, with projections indicating that it will reach a staggering US$1.72bn by the year 2024.
Furthermore, this market is expected to exhibit a promising annual growth rate (CAGR 2024-2029) of 6.65%, leading to a substantial increase in market volume, estimated to be around US$2.37bn by 2029.
When compared on a global scale, United States is anticipated to generate the highest revenue in this market, with an impressive figure of US$37.84bn projected for the year 2024.
France's anti-diabetes drug market is experiencing a surge in demand due to the country's high prevalence of diabetes and increasing awareness about the importance of managing the disease.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in France has seen significant growth in recent years, driven by various factors.

Customer preferences: Patients in France with diabetes are increasingly seeking more effective and convenient treatment options. There is a growing demand for drugs that not only control blood sugar levels but also help manage the associated symptoms and complications of the disease. Patients are also looking for drugs that have fewer side effects, are easy to administer, and fit into their daily routines.

Trends in the market: The Anti-Diabetes Drugs market in France has been witnessing a shift towards newer, more innovative drugs. There has been a rise in the use of GLP-1 receptor agonists and SGLT-2 inhibitors, which have shown to be effective in controlling blood sugar levels and reducing cardiovascular risk. There has also been an increase in the use of combination therapies, where multiple drugs are used together to achieve better outcomes. Additionally, there has been a growing trend towards personalized medicine, where treatments are tailored to the individual needs of patients.

Local special circumstances: France has a well-established healthcare system that provides universal coverage to its citizens. The government heavily regulates drug prices, which has led to lower prices for anti-diabetes drugs compared to other countries. This has made these drugs more accessible to patients and has contributed to the growth of the market. There is also a strong emphasis on preventive care in France, which has led to increased screening and early detection of diabetes.

Underlying macroeconomic factors: The aging population in France has led to a higher prevalence of diabetes, which has contributed to the growth of the Anti-Diabetes Drugs market. Additionally, there has been a rise in obesity rates, which is a major risk factor for developing diabetes. The French government has taken several initiatives to address this issue, such as implementing a sugar tax and promoting healthy eating and physical activity. These measures are expected to have a positive impact on the Anti-Diabetes Drugs market in the long run.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.